Please login to the form below

Not currently logged in
Email:
Password:

Onivyde

This page shows the latest Onivyde news and features for those working in and with pharma, biotech and healthcare.

Revenue growth at Ipsen numbs pain of palovarotene calamity

Revenue growth at Ipsen numbs pain of palovarotene calamity

It also has data due in the coming months for Onivyde (irinotecan liposome injection) in first-line pancreatic cancer and second-line small cell lung cancer.  Onivyde grew 17% to 134m

Latest news

  • Shire offloads oncology unit to Servier for $2.4bn Shire offloads oncology unit to Servier for $2.4bn

    The French drugmaker will also acquire Oncaspar and Onivyde as part of the deal. ... The Dublin-based company said the deal covers its already-marketed drug Oncaspar (pergaspargase) for acute lymphoblastic leukaemia (ALL), as well as ex-US rights to

  • NICE knocks-back Shire's pancreatic cancer drug Onivyde NICE knocks-back Shire's pancreatic cancer drug Onivyde

    NICE has ruled that Shire’s pancreatic cancer drug Onivyde (pegylated liposomal irinotecan) is not a cost-effective use of NHS resources. ... But in its final guidance it concluded the incremental cost-effectiveness ratio (ICERs) for Onivyde with 5-FU

  • Ipsen buys cancer business from stripped down Merrimack Ipsen buys cancer business from stripped down Merrimack

    Deal includes pancreatic cancer therapy Onivyde which it hopes will gain first-line approval. ... French drugmaker Ipsen will pay $575m to buy Merrimack Pharma's oncology business, headed by second-line pancreatic cancer therapy Onivyde.

  • Shire wins EU licence for pancreatic cancer drug Onivyde Shire wins EU licence for pancreatic cancer drug Onivyde

    Combination treatment is the first approved for this patient population. The European Commission has approved Shire's Onivyde for the treatment of adults with metastatic adenocarcinoma of the pancreas, making it ... As such Onivyde marks a first for this

  • HIV prevention pill heads July CHMP recommendations HIV prevention pill heads July CHMP recommendations

    The CHMP also gave a positive opinion for Shire's Onivyde (pegylated irinotecan liposomal formulation) for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin,

More from news
Approximately 5 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics